Chardan Capital Has Negative Outlook of SNTI FY2024 Earnings

Senti Biosciences, Inc. (NASDAQ:SNTI) – Research analysts at Chardan Capital dropped their FY2024 earnings estimates for Senti Biosciences in a report issued on Wednesday, December 4th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings per share of ($14.54) for the year, down from their prior forecast of ($9.58). Chardan Capital has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Senti Biosciences’ current full-year earnings is ($9.58) per share. Chardan Capital also issued estimates for Senti Biosciences’ FY2025 earnings at ($1.88) EPS.

Senti Biosciences Trading Down 11.3 %

NASDAQ SNTI opened at $5.50 on Monday. The company has a market capitalization of $25.25 million, a PE ratio of -0.35 and a beta of 2.69. The stock has a 50-day simple moving average of $2.69 and a 200 day simple moving average of $2.71. Senti Biosciences has a 12 month low of $1.52 and a 12 month high of $16.94.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.